CERS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

59.31M

+16.72%

-0.025

+25%

51.63M

+19.41%

-0.005

-50%

59.66M

+13.76%

-0.030

-25%

Estimates Revision

The market is revising Upward the revenue expectations for Cerus Corporation (CERS) for FY2025, with the revenue forecasts being adjusted by 1.37% over the past three months. During the same period, the stock price has changed by 28.75%.

Revenue Estimates for FY2025

Revise Upward

+1.37%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+28.75%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERS is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

4.50

High

5.00

Current: 0.000

Low

4.00

Averages

4.50

High

5.00

TD Cowen

Buy

maintain

2025-12-23

Reason

TD Cowen

Price Target

2025-12-23

maintain

Buy

Reason

TD Cowen says that Cerus' Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus' double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

2025-02-21

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

2025-02-21

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Cerus Corp (CERS.O) is -56.29, compared to its 5-year average forward P/E of -20.05. For a more detailed relative valuation and DCF analysis to assess Cerus Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-20.05

Current PE

-56.29

Overvalued PE

-11.06

Undervalued PE

-29.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.16

Current EV/EBITDA

27.62

Overvalued EV/EBITDA

58.03

Undervalued EV/EBITDA

-68.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.66

Current PS

1.63

Overvalued PS

6.24

Undervalued PS

1.08

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CERS News & Events

Events Timeline

No data

News

2.0

2025-12-11NASDAQ.COM

Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying

1.0

2025-10-21Newsfilter

Cerus Corporation Unveils Abstracts and Hosts Industry Workshop on IFC at the 2025 AABB Annual Meeting

4.0

2025-09-21NASDAQ.COM

Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - September 20, 2025

People Also Watch

Frequently Asked Questions

What is Cerus Corp (CERS) stock price today?

The current price of CERS is 2.06 USD — it has decreased -1.44 % in the last trading day.

What is Cerus Corp (CERS)'s business?

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

What is the price predicton of CERS Stock?

What is Cerus Corp (CERS)'s revenue for the last quarter?

Cerus Corp revenue for the last quarter amounts to 60.24M USD, increased 18.91 % YoY.

What is Cerus Corp (CERS)'s earnings per share (EPS) for the last quarter?

Cerus Corp. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Cerus Corp (CERS)'s fundamentals?

How many employees does Cerus Corp (CERS). have?

Cerus Corp (CERS) has 281 emplpoyees as of January 10 2026.

What is Cerus Corp (CERS) market cap?

Today CERS has the market capitalization of 395.70M USD.